Cost-effectiveness of Paxlovid in reducing severe COVID-19 and mortality in China
Frontiers in Public Health, 2023 ObjectivesTo assess the cost-effectiveness of Paxlovid in reducing severe COVID-19 and its associated morality, and to investigate the affordable price of Paxlovid in China.Materials and methodsUsing a Markov model, two interventions by Paxlovid ...
Weina Zhang +5 more
exaly +3 more sources
Effectiveness and Safety of Nirmatrelvir/Ritonavir (Paxlovid) Versus Remdesivir in COVID‐19: A Systematic Review and Meta‐Analysis of Retrospective Studies [PDF]
Health Science ReportsBackground and Aim Nirmatrelvir/ritonavir (Paxlovid) and remdesivir are antiviral agents that have been widely used in the management of patients with Coronavirus disease 2019 (COVID‐19). This systematic review and meta‐analysis were conducted to compare
Arash Akbarzadeh +7 more
doaj +2 more sources
Activation of PXR causes drug interactions with Paxlovid in transgenic mice
Acta Pharmaceutica Sinica B, 2023 Paxlovid is a nirmatrelvir (NMV) and ritonavir (RTV) co-packaged medication used for the treatment of coronavirus disease 2019 (COVID-19). The active component of Paxlovid is NMV and RTV is a pharmacokinetic booster.
Aaron S Devanathan +2 more
exaly +3 more sources
European Journal of Case Reports in Internal Medicine, 2022 Tacrolimus is commonly used as a prophylactic against acute rejection in transplant patients. Tacrolimus toxicity has numerous presentations that have been well documented in the literature and can be induced by a wide variety of agents.
Aaisha Shah +3 more
doaj +3 more sources
A Retrospective Observational Study on COVID-19 Patients Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID) [PDF]
Pulmonary TherapyIntroduction This study was undertaken in COVID-19 patients treated with and without Paxlovid™ (Paxlovid) in an outpatient setting to determine hospitalization from the community.
Mariam M. Murad +13 more
doaj +2 more sources
Paxlovid shows organ-specific and age-specific impacts on risk of developing post-acute sequelae of COVID-19 [PDF]
Communications MedicineBackground The impact of antiviral therapies, including Paxlovid, on post-acute sequelae of COVID-19 (PASC) remains inconclusive. Methods We analyzed data from 19,413 patients (age > 18) from a validated PASC research cohort in New England who ...
Alaleh Azhir +4 more
doaj +2 more sources
Frontiers in Pediatrics, 2023 ObjectiveTo summarize the clinical characteristics of children with hematological malignancies co-infected with novel coronavirus and explore the safety and effectiveness of Paxlovid treatment.MethodsFrom December 10, 2022, to January 20, 2023, the ...
Hongman Xue, Yixian Li, Yucai Cheng
exaly +3 more sources
Vaccines, 2023 COVID-19 virus, since the detection of the first case in Wuhan in 2019, has caused a worldwide pandemic with significant human, economic and social costs.
Rahul Shekhar +2 more
exaly +3 more sources
Development and application of a UHPLC-MS/MS method for the simultaneous determination of firmonertinib and its main metabolite AST-5902 in rat plasma: a study on the in vivo drug interaction between firmonertinib and paxlovid [PDF]
Frontiers in PharmacologyDue to the potential occurrence of drug interactions, the combined application of firmonertinib and paxlovid carries a relatively high risk. Nevertheless, as of now, there has been no comprehensive research on the interaction between firmonertinib and ...
Peng-Fei Tang +5 more
doaj +2 more sources
Paxlovid for the treatment of severe or critical COVID-19 in children [PDF]
BMC PediatricsBackground Paxlovid, known for its efficacy against SARS-CoV-2, is currently limited in its use for treating pediatric COVID-19, particularly in severe or critical cases.
Linjuan Xiang +15 more
doaj +2 more sources